Literature DB >> 29578237

Nutritional supplements for patients being treated for active visceral leishmaniasis.

Estefanía Custodio1, Jesús López-Alcalde, Mercè Herrero, Carmen Bouza, Carolina Jimenez, Stefan Storcksdieck Genannt Bonsmann, Theodora Mouratidou, Teresa López-Cuadrado, Agustin Benito, Jorge Alvar.   

Abstract

BACKGROUND: Visceral leishmaniasis (VL) is a disease caused by a parasite, which can lead to death if untreated. Poor nutritional status hastens the progression of VL infection, and VL worsens malnutrition status. Malnutrition is one of the poor prognostic factors identified for leishmaniasis. However, the effects of nutritional supplementation in people treated for VL are not known.
OBJECTIVES: To assess the effects of oral nutritional supplements in people being treated with anti-leishmanial drug therapy for VL. SEARCH
METHODS: We searched the Cochrane Infectious Diseases Group (CIDG) Specialized Register, CENTRAL, MEDLINE, Embase, LILACS, and two trial registers up to 12 September 2017. We checked conference proceedings and WHO consultative meeting reports, the reference lists of key documents and existing reviews, and contacted experts and nutritional supplement companies. SELECTION CRITERIA: Randomized controlled trials (RCTs), quasi-randomized controlled trials (quasi-RCTs), and non-randomized controlled trials (NRCTs) of any oral nutritional supplement, compared to no nutritional intervention, placebo, or dietary advice alone, in people being treated for VL. DATA COLLECTION AND ANALYSIS: Two review authors independently screened the literature search results for studies that met the inclusion criteria. We had planned for two review authors to independently extract data and assess the risk of bias of the included studies. We planned to follow the Cochrane standard methodological procedures for assessing risk of bias and analysing the data. MAIN
RESULTS: We identified no eligible studies for this review, either completed or ongoing. AUTHORS'
CONCLUSIONS: We found no studies, either completed or ongoing, that assessed the effects of oral nutritional supplements in people with VL who were being treated with anti-leishmanial drug therapy. Thus, we could not draw any conclusions on the impact of these interventions on primary cure of VL, definitive cure of VL, treatment completion, self-reported recovery from illness or resolution of symptoms, weight gain, increased skinfold thickness, other measures of lean or total mass, or growth in children.This absence of evidence should not be interpreted as evidence of no effect for nutritional supplements in people under VL treatment. It means that we did not identify research that fulfilled our review inclusion criteria.The effects of oral nutritional supplements in people with VL who are being treated with anti-leishmanial drug therapy have yet to be determined by rigorous experimental studies, such as cluster-randomized trials, that focus on outcomes relevant for patients.

Entities:  

Mesh:

Year:  2018        PMID: 29578237      PMCID: PMC6494195          DOI: 10.1002/14651858.CD012261.pub2

Source DB:  PubMed          Journal:  Cochrane Database Syst Rev        ISSN: 1361-6137


  60 in total

1.  Randomised trials in child health in developing countries 2011.

Authors:  T Duke
Journal:  Ann Trop Paediatr       Date:  2011

2.  Improving outcome of treatment of kala-azar by supplementation of amphotericin B with physiologic saline and potassium chloride.

Authors:  Chandeshwar P Thakur; A Kumar; Dipendra K Mitra; Ambak Roy; Arun Kumar Sinha; Alok Ranjan
Journal:  Am J Trop Med Hyg       Date:  2010-11       Impact factor: 2.345

Review 3.  The COMET Handbook: version 1.0.

Authors:  Paula R Williamson; Douglas G Altman; Heather Bagley; Karen L Barnes; Jane M Blazeby; Sara T Brookes; Mike Clarke; Elizabeth Gargon; Sarah Gorst; Nicola Harman; Jamie J Kirkham; Angus McNair; Cecilia A C Prinsen; Jochen Schmitt; Caroline B Terwee; Bridget Young
Journal:  Trials       Date:  2017-06-20       Impact factor: 2.279

4.  We need more randomized trials in nutrition-preferably large, long-term, and with negative results.

Authors:  John Pa Ioannidis
Journal:  Am J Clin Nutr       Date:  2016-05-04       Impact factor: 7.045

Review 5.  Treatment options for visceral leishmaniasis: a systematic review of clinical studies done in India, 1980-2004.

Authors:  Piero L Olliaro; Philippe J Guerin; Sibylle Gerstl; Astrid Aga Haaskjold; John-Arne Rottingen; Shyam Sundar
Journal:  Lancet Infect Dis       Date:  2005-12       Impact factor: 25.071

6.  Clinical aspects of paediatric visceral leishmaniasis in North-west Ethiopia.

Authors:  Ermias Diro; Lutgarde Lynen; Berhane Gebregziabiher; Abraham Assefa; Wubishet Lakew; Zewdu Belew; Asrat Hailu; Marleen Boelaert; Johan van Griensven
Journal:  Trop Med Int Health       Date:  2014-10-20       Impact factor: 2.622

7.  A randomized trial of direct-to-patient communication to enhance adherence to beta-blocker therapy following myocardial infarction.

Authors:  David H Smith; Judith M Kramer; Nancy Perrin; Richard Platt; Douglas W Roblin; Kimberly Lane; Michael Goodman; Winnie W Nelson; Xiuhai Yang; Stephen B Soumerai
Journal:  Arch Intern Med       Date:  2008-03-10

Review 8.  Rapid tests for the diagnosis of visceral leishmaniasis in patients with suspected disease.

Authors:  Marleen Boelaert; Kristien Verdonck; Joris Menten; Temmy Sunyoto; Johan van Griensven; Francois Chappuis; Suman Rijal
Journal:  Cochrane Database Syst Rev       Date:  2014-06-20

Review 9.  Association of Industry Sponsorship With Outcomes of Nutrition Studies: A Systematic Review and Meta-analysis.

Authors:  Nicholas Chartres; Alice Fabbri; Lisa A Bero
Journal:  JAMA Intern Med       Date:  2016-12-01       Impact factor: 21.873

10.  Dual immune modulatory effect of vitamin A in human visceral leishmaniasis.

Authors:  Bruna L Lima Maciel; Bruna L Lima Maciel; Joanna Gardel Valverde; João Firmino Rodrigues-Neto; Francisco Freire-Neto; Tatjana S L Keesen; Selma Maria Bezerra Jeronimo
Journal:  PLoS One       Date:  2014-09-30       Impact factor: 3.240

View more
  4 in total

Review 1.  Nutritional supplements for patients being treated for active visceral leishmaniasis.

Authors:  Estefanía Custodio; Jesús López-Alcalde; Mercè Herrero; Carmen Bouza; Carolina Jimenez; Stefan Storcksdieck Genannt Bonsmann; Theodora Mouratidou; Teresa López-Cuadrado; Agustin Benito; Jorge Alvar
Journal:  Cochrane Database Syst Rev       Date:  2018-03-26

2.  Barriers to access to visceral leishmaniasis diagnosis and care among seasonal mobile workers in Western Tigray, Northern Ethiopia: A qualitative study.

Authors:  Rebecca Marie Coulborn; Tesfay Gebregzabher Gebrehiwot; Martin Schneider; Sibylle Gerstl; Cherinet Adera; Mercè Herrero; Klaudia Porten; Margriet den Boer; Koert Ritmeijer; Jorge Alvar; Abrahim Hassen; Afework Mulugeta
Journal:  PLoS Negl Trop Dis       Date:  2018-11-08

Review 3.  Evidence map of diagnosis, treatment, prognosis, prevention, and control in visceral leishmaniasis.

Authors:  Andressa Barros Ibiapina; Francisca Miriane de Araújo Batista; Bruno Guedes Alcoforado Aguiar; Vagner José Mendonça; Dorcas Lamounier Costa; Carlos Henrique Nery Costa; Carmen Verônica Mendes Abdala
Journal:  Rev Panam Salud Publica       Date:  2022-07-20

Review 4.  New insights into leishmaniasis in the immunosuppressed.

Authors:  Hannah Akuffo; Carlos Costa; Johan van Griensven; Sakib Burza; Javier Moreno; Mercè Herrero
Journal:  PLoS Negl Trop Dis       Date:  2018-05-10
  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.